-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, August 12 News, on August 10, the CDE official website showed that Dongyang Pharmaceutical’s Class 1 new drug HEC93077 tablets have been approved by clinical trials and are intended to be used for the treatment of gout with hyperuricemia
.
According to data from Meinenet, in 2020, the sales of terminal anti-gout preparations in Chinese public medical institutions and physical pharmacies in cities in China will exceed 3 billion yuan
.
Since 2021, Dongyang Sunshine has already approved 6 Class 1 new drugs for clinical trials
.
The new class 1 drug HEC93077 tablets are intended to treat gout with hyperuricemia
.
Tosun Pharmaceutical’s current product line already has two anti-gout preparations, febuxostat tablets and benzbromarone tablets
.
According to data from Menet.
com, in recent years , the market size of terminal anti-gout preparations in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies has continued to rise, with sales breakthroughs in 2020 3 billion yuan
.
Affected by the inclusion of febuxostat in centralized procurement, the terminal sales growth of anti-gout preparations in China's public medical institutions will slow down significantly in 2020, while the terminal sales of physical pharmacies in Chinese cities can still maintain double-digit growth
.
Chinese cities entity pharmacy terminal anti-gout preparations sales (unit: million) Source: m entity within the network of urban pharmacies terminal competition China at present, many domestic enterprises layout anti-gout drug innovation, research and development progress forward has Hengrui Medicine 's SHR4640 piece, a sea of HP501 Pharmaceutical sustained-release tablets, Ying Li Pharmaceutical films such as YL-90148
.
Since the beginning of this year, Dongyang Sun Pharmaceuticals has received clinical approval for 6 new class 1 drugs, including HEC73077 tablets, HEC116094HCl·3H2O tablets, HEC88473 injection, frexidine tablets, ifenidone hydrochloride tablets and HEC93077 tablets.
.
Data source: Mi Neiwang database, CDE Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the city entity that covers 293 prefectures and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors the entire category Pharmacy database
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
According to data from Meinenet, in 2020, the sales of terminal anti-gout preparations in Chinese public medical institutions and physical pharmacies in cities in China will exceed 3 billion yuan
.
Since 2021, Dongyang Sunshine has already approved 6 Class 1 new drugs for clinical trials
.
The new class 1 drug HEC93077 tablets are intended to treat gout with hyperuricemia
.
Tosun Pharmaceutical’s current product line already has two anti-gout preparations, febuxostat tablets and benzbromarone tablets
.
According to data from Menet.
com, in recent years , the market size of terminal anti-gout preparations in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies has continued to rise, with sales breakthroughs in 2020 3 billion yuan
.
Affected by the inclusion of febuxostat in centralized procurement, the terminal sales growth of anti-gout preparations in China's public medical institutions will slow down significantly in 2020, while the terminal sales of physical pharmacies in Chinese cities can still maintain double-digit growth
.
Chinese cities entity pharmacy terminal anti-gout preparations sales (unit: million) Source: m entity within the network of urban pharmacies terminal competition China at present, many domestic enterprises layout anti-gout drug innovation, research and development progress forward has Hengrui Medicine 's SHR4640 piece, a sea of HP501 Pharmaceutical sustained-release tablets, Ying Li Pharmaceutical films such as YL-90148
.
Since the beginning of this year, Dongyang Sun Pharmaceuticals has received clinical approval for 6 new class 1 drugs, including HEC73077 tablets, HEC116094HCl·3H2O tablets, HEC88473 injection, frexidine tablets, ifenidone hydrochloride tablets and HEC93077 tablets.
.
Data source: Mi Neiwang database, CDE Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the city entity that covers 293 prefectures and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors the entire category Pharmacy database
.
The above sales are calculated based on the average retail price of the product at the terminal
.
